RxDoctor Payments DataLook up a doctor →

Nathaniel Whaley, MD

Neurology · Johnson City, TNNPI 1245213545

Payments from drug & device makers

$739,960in general payments, 2019–2025

Across 1,588 payments — averaging $465.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$388K
  • Adamas Pharmaceuticals, Inc.$150K
  • Amgen$39K
  • Eli Lilly$27K
  • Avanir Pharmaceuticals, Inc.$27K
  • Biohaven Pharmaceuticals, Inc.$19K
  • plus $90K from 54 others
$19,072in research payments, 2019–2025

Across 2 payments — averaging $9536.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$19K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis98$387,508
Adamas Pharmaceuticals, Inc.60$150,138
Amgen(2 entities)36$38,998
Eli Lilly3$27,015
Avanir Pharmaceuticals, Inc.47$26,724
Biohaven Pharmaceuticals, Inc.42$19,032
Biogen93$18,357
Argenx US, Inc.39$14,208
AstraZeneca(2 entities)71$10,848
AbbVie(2 entities)131$9,392
Sanofi30$6,940
EMD Serono, Inc.28$5,471
Biohaven Pharmaceutical Holding Company Ltd.23$4,826
Genentech USA, Inc.45$2,874
Lundbeck LLC57$2,320
UCB, Inc.82$1,827
Neurelis, Inc.42$1,125
MDD US Operations, LLC54$1,021
Neurocrine Biosciences, Inc.45$828
Eisai Inc.36$691
Teva Pharmaceuticals USA, Inc.35$688
Lilly USA, LLC41$669
Supernus Pharmaceuticals, Inc.34$637
Pfizer50$583
Acadia Pharmaceuticals Inc40$567
CSL Behring23$480
TG Therapeutics, Inc.14$450
Impel Pharmaceuticals Inc.40$439
Jazz Pharmaceuticals Inc.18$412
Amylyx Pharmaceuticals, Inc.1$400
Amneal Pharmaceuticals LLC20$346
Sunovion Pharmaceuticals Inc.24$291
Greenwich Biosciences, Inc.8$274
Johnson & Johnson10$251
Grifols USA, LLC12$232
Mallinckrodt Hospital Products Inc.9$210
SK Life Science, Inc.10$203
Arbor Pharmaceuticals, Inc.11$183
Harmony Biosciences LLC8$180
Otsuka America Pharmaceutical, Inc.10$178
Kyowa Kirin, Inc.9$178
Sumitomo Pharma America, Inc.13$171
Bristol Myers Squibb9$165
Corium, LLC7$142
Medtronic4$140
Catalyst Pharmaceuticals, Inc.6$132
Vanda Pharmaceuticals Inc.5$125
Acorda Therapeutics, Inc5$124
Takeda Pharmaceuticals U.S.A., Inc.4$104
Axsome Therapeutics, Inc.4$92
Scilex Pharmaceuticals Inc.5$91
Alnylam Pharmaceuticals Inc.4$78
Sanofi-aventis U.S. LLC4$73
Zyla Life Sciences, Inc.5$70
Tanabe Pharma America, Inc.3$57
Neuropace, Inc.1$51
E.r. Squibb & Sons, L.L.C.3$48
Impel Pharmaceuticals LLC2$42
Mallinckrodt Enterprises LLC2$37
Azurity Pharmaceuticals, Inc.2$32

How this compares

$739,960 in reported general payments places this provider in the 90th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee →

Medicare billing

Part B allowed, 2024
$2,723,648
Medicare patients
434
Services billed
58,400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Johnson City

See the full list for Tennessee →

Where these figures come from

Is this you, or does something look wrong? →